# Navinci Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/navinci-diagnostics

- Industry: Biotechnology
- Headquarters: Uppsala, Sweden
- Website: www.navinci.se
- Total disclosed funding: $8.6M
- Latest round: Series A (Jul 12, 2022)
- Investors on record: 4

## About

Founded in 2004 by Ulf Landegren and Björn Ekström and based in Uppsala, Sweden, Navinci Diagnostics AB, formerly known as Olink Bioscience, engages in developing analytical methods for nucleic acids and proteins, spotting business prospects, and launching profitable products. In 2016, Olink Bioscience became Navinci Diagnostics. As of January 2023, Robert Gunnarsson serves as the CEO of the company. In July 2022, Navinci Diagnostics AB raised SEK 90 million in Series A funding from Segulah Medical Acceleration, including Beijer Ventures, Landegren Gene Technology AB, and Nexttobe AB.

The company offers products such as NaveniFlex MR, NaveniFlex GM, NaveniFlex GR, NaveniFlex MM, NaveniFlex RR, and the NaveniFlex Control kit. It offers Naveni TriFlex Cell products, such as Naveni TriFlex Cell MR, and NaveniBright products, such as NaveniBright AP and NaveniBright HRP, as well as target-specific products, including Naveni PTMs (post-translational modifications) and Naveni PPIs (protein-protein interactions).

The firm provides Naveni™ Proximity Ligation Technology platform, which provides accurate data with quantifiable and precise staining. Navinci's platform’s benefits include clear target detection, consistency in staining, reproducibility, the possibility to detect low abundance proteins, the detection of protein-protein interactions, and more.

The organization plans to use the July 2022 funding to expedite global commercialization and collaborate with businesses that have complementary technology in order to provide full solutions for its clients.

## Funding rounds

- Series A, Jul 12, 2022, $8.6M — Segulah Medical Acceleration, Landegren Gene Technology AB, Nexttobe AB, Beijer Ventures

## Investors

- Segulah Medical Acceleration (https://capitalatlas.ai/funds/segulah-medical-acceleration) — Series A
- Landegren Gene Technology AB — Series A
- Nexttobe AB (https://capitalatlas.ai/funds/nexttobe-ab) — Series A
- Beijer Ventures (https://capitalatlas.ai/funds/beijer-ventures) — Series A